FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588404810> ?p ?o ?g. }

• W2588404810 endingPage "669" @default.
• W2588404810 startingPage "660" @default.
• W2588404810 abstract "Abstract Resistance to second-generation androgen receptor (AR) antagonists and CYP17 inhibitors in patients with castration-resistant prostate cancer (CRPC) develops rapidly through reactivation of the androgen signaling axis and has been attributed to AR overexpression, production of constitutively active AR splice variants, or the selection for AR mutants with altered ligand-binding specificity. It has been established that androgens induce cell-cycle progression, in part, through upregulation of cyclin D1 (CCND1) expression and subsequent activation of cyclin-dependent kinases 4 and 6 (CDK4/6). Thus, the efficacy of the newly described CDK4/6 inhibitors (G1T28 and G1T38), docetaxel and enzalutamide, was evaluated as single agents in clinically relevant in vitro and in vivo models of hormone-sensitive and treatment-resistant prostate cancer. CDK4/6 inhibition (CDK4/6i) was as effective as docetaxel in animal models of treatment-resistant CRPC but exhibited significantly less toxicity. The in vivo effects were durable and importantly were observed in prostate cancer cells expressing wild-type AR, AR mutants, and those that have lost AR expression. CDK4/6i was also effective in prostate tumor models expressing the AR-V7 variant or the AR F876L mutation, both of which are associated with treatment resistance. Furthermore, CDK4/6i was effective in prostate cancer models where AR expression was lost. It is concluded that CDK4/6 inhibitors are a viable alternative to taxanes as therapeutic interventions in endocrine therapy–refractory CRPC. Implications: The preclinical efficacy of CDK4/6 monotherapy observed here suggests the need for near-term clinical studies of these agents in advanced prostate cancer. Mol Cancer Res; 15(6); 660–9. ©2017 AACR." @default.
• W2588404810 created "2017-02-24" @default.
• W2588404810 creator A5010992392 @default.
• W2588404810 creator A5012103903 @default.
• W2588404810 creator A5015846969 @default.
• W2588404810 creator A5030132149 @default.
• W2588404810 creator A5036776589 @default.
• W2588404810 creator A5037332413 @default.
• W2588404810 creator A5037408779 @default.
• W2588404810 creator A5055459877 @default.
• W2588404810 creator A5062055452 @default.
• W2588404810 creator A5063379905 @default.
• W2588404810 creator A5066983733 @default.
• W2588404810 creator A5078598967 @default.
• W2588404810 creator A5080704333 @default.
• W2588404810 creator A5083074774 @default.
• W2588404810 date "2017-06-01" @default.
• W2588404810 modified "2023-10-12" @default.
• W2588404810 title "CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC" @default.
• W2588404810 cites W1833796513 @default.
• W2588404810 cites W1835371258 @default.
• W2588404810 cites W1844925317 @default.
• W2588404810 cites W1863237805 @default.
• W2588404810 cites W1968100517 @default.
• W2588404810 cites W2040564571 @default.
• W2588404810 cites W2064293531 @default.
• W2588404810 cites W2080439368 @default.
• W2588404810 cites W2086082161 @default.
• W2588404810 cites W2096979580 @default.
• W2588404810 cites W2110534364 @default.
• W2588404810 cites W2121846636 @default.
• W2588404810 cites W2123526148 @default.
• W2588404810 cites W2130189600 @default.
• W2588404810 cites W2134988422 @default.
• W2588404810 cites W2136158663 @default.
• W2588404810 cites W2144790402 @default.
• W2588404810 cites W2156923287 @default.
• W2588404810 cites W2166918329 @default.
• W2588404810 cites W2167277055 @default.
• W2588404810 cites W2167749314 @default.
• W2588404810 cites W2170552969 @default.
• W2588404810 cites W2171450779 @default.
• W2588404810 cites W2181283187 @default.
• W2588404810 cites W2255638054 @default.
• W2588404810 cites W2268588237 @default.
• W2588404810 cites W2290950904 @default.
• W2588404810 cites W2309969893 @default.
• W2588404810 cites W2313842338 @default.
• W2588404810 cites W2340799873 @default.
• W2588404810 cites W2395632780 @default.
• W2588404810 cites W2402797587 @default.
• W2588404810 doi "https://doi.org/10.1158/1541-7786.mcr-17-0028" @default.
• W2588404810 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6295664" @default.
• W2588404810 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28209757" @default.
• W2588404810 hasPublicationYear "2017" @default.
• W2588404810 type Work @default.
• W2588404810 sameAs 2588404810 @default.
• W2588404810 citedByCount "20" @default.
• W2588404810 countsByYear W25884048102017 @default.
• W2588404810 countsByYear W25884048102018 @default.
• W2588404810 countsByYear W25884048102019 @default.
• W2588404810 countsByYear W25884048102020 @default.
• W2588404810 countsByYear W25884048102021 @default.
• W2588404810 countsByYear W25884048102022 @default.
• W2588404810 crossrefType "journal-article" @default.
• W2588404810 hasAuthorship W2588404810A5010992392 @default.
• W2588404810 hasAuthorship W2588404810A5012103903 @default.
• W2588404810 hasAuthorship W2588404810A5015846969 @default.
• W2588404810 hasAuthorship W2588404810A5030132149 @default.
• W2588404810 hasAuthorship W2588404810A5036776589 @default.
• W2588404810 hasAuthorship W2588404810A5037332413 @default.
• W2588404810 hasAuthorship W2588404810A5037408779 @default.
• W2588404810 hasAuthorship W2588404810A5055459877 @default.
• W2588404810 hasAuthorship W2588404810A5062055452 @default.
• W2588404810 hasAuthorship W2588404810A5063379905 @default.
• W2588404810 hasAuthorship W2588404810A5066983733 @default.
• W2588404810 hasAuthorship W2588404810A5078598967 @default.
• W2588404810 hasAuthorship W2588404810A5080704333 @default.
• W2588404810 hasAuthorship W2588404810A5083074774 @default.
• W2588404810 hasBestOaLocation W25884048101 @default.
• W2588404810 hasConcept C121608353 @default.
• W2588404810 hasConcept C126322002 @default.
• W2588404810 hasConcept C150903083 @default.
• W2588404810 hasConcept C199649820 @default.
• W2588404810 hasConcept C199835354 @default.
• W2588404810 hasConcept C207001950 @default.
• W2588404810 hasConcept C2775930923 @default.
• W2588404810 hasConcept C2776551883 @default.
• W2588404810 hasConcept C2779744173 @default.
• W2588404810 hasConcept C2780192828 @default.
• W2588404810 hasConcept C2781190966 @default.
• W2588404810 hasConcept C29537977 @default.
• W2588404810 hasConcept C502942594 @default.
• W2588404810 hasConcept C51853150 @default.
• W2588404810 hasConcept C530470458 @default.
• W2588404810 hasConcept C61367390 @default.
• W2588404810 hasConcept C71924100 @default.
• W2588404810 hasConcept C82495950 @default.

• next